Teva Pharmaceutical Industries Limited (0LER.L)
| Previous close | 7.35 |
| Open | 7.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 7.29 - 7.33 |
| 52-week range | 7.10 - 11.25 |
| Volume | |
| Avg. volume | 13,204 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Israeli economy has proven to thrive despite crisis: Expert
Over the weekend, Iran launched a direct attack on Israel. Although Israel successfully intercepted the drones and missiles, the potential for an Israeli retaliation remains uncertain. David Blumberg of Blumberg Capital joins Yahoo Finance to discuss the state of the Israeli economy in light of these developments. Blumberg claims that Israelis are "somewhat used to these types of things." Blumberg notes that over the past 25 years, the country has weathered numerous crises, but has achieved consistent growth. He points to Israel's GDP per capita of $54,000, which exceeds that of some of the world's largest economies, as evidence of the economy's ability to "thrive despite and through downturns." For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Yahoo Finance Video
Teva Pharmaceutical upgraded at Piper Sandler
Analysts at Piper Sandler raised their rating on Teva Pharmaceutical (TEVA) to Overweight from Neutral. They also boosted the price target to $19 from $12. The firm lists several reasons for the upgrade, including an improved outlook on the company's capital structure and the strength of its neuroscience business. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
- Yahoo Finance Video
How Teva's CEO is implementing his 'pivot to growth' strategy
Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy. Teva CEO Richard Francis joins Yahoo Finance Live alongside Health Reporter Anjalee Khemlani to discuss the latest quarterly earnings report and plans for the company moving forward. Francis comments on his pivot to growth strategy: "When I came in and we did the pivot-to-growth strategy, we looked across all the businesses at Teva. We understood, where did we want to grow? We clearly want to grow our innovative business and our generics business... The API business, TAPI, its the second largest API manufacturer in the world, it is world class. But two things we saw and analyzed it, which is, one, it's constrained being part of Teva. The global API market is an $85 billion market..." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino
